Gastric Cancer

, Volume 18, Issue 4, pp 774–783 | Cite as

Inhibition of β-catenin and STAT3 with a curcumin analog suppresses gastric carcinogenesis in vivo

  • Yoshihiko Uehara
  • Masahiro Inoue
  • Koji Fukuda
  • Hiroyuki Yamakoshi
  • Yoshio Hosoi
  • Hiroaki Kanda
  • Masanobu Oshima
  • Yoshiharu Iwabuchi
  • Hiroyuki ShibataEmail author
Open Access
Original Article



Potent chemotherapy for advanced gastric cancer has not been completely established. Many molecularly targeted therapies are under investigation, but their therapeutic outcomes are not promising because they do not target specific and/or critical targets of gastric carcinogenesis. Although the molecular basis of gastric carcinogenesis remains poorly understood, nuclear localization of β-catenin was observed in approximately 50 % of gastric cancer specimens. Recent studies have suggested that activation of signal transducer and activator of transcription 3 (STAT3) contributes to gastric carcinogenesis in a mouse model. A newly synthesized curcumin analog has inhibitory potential against β-catenin and STAT3.


Using a transgenic mouse model of gastric cancer in which β-catenin, cyclooxygenase 2, and microsomal prostaglandin E synthase 1 activation is induced, we examined a curcumin analog with the most enhanced potential for treating gastric cancer through oral administration. Inhibition of these targets was demonstrated using microarray and immunohistochemical analyses.


The curcumin analog GO-Y031 decreased the incidence of gastric carcinogenesis to 54.5 % of that of the control (50.0 % vs 91.7 %, p = 0.043), and tumor size was reduced to 51.6 % of that of the control (1.6 mm vs 3.1 mm, p = 0.03). β-Catenin and STAT3 levels were suppressed to 26.2 % (p = 0.00023) and 44.8 % (p = 0.025), respectively, of those of the control. Moreover, macrophage infiltration was suppressed with GO-Y031.


β-Catenin and STAT3 can be pharmacologically inhibited in vivo with a curcumin analog, which effectively inhibits β-catenin and STAT3.


Analog β-Catenin Curcumin Gastric cancer Signal transducer and activator of transcription 3 


Gastric cancer is a malignancy with a high incidence, particularly in Asia [1, 2]. In three Asian countries—Japan, Korea, and China—gastric cancer accounts for approximately 60 % of new cancer patients [1, 2]. However, the prevention and early detection of gastric cancer remains difficult, and surgery is the only current treatment for this cancer. Advanced-stage gastric cancer is diagnosed in many patients, and recurrence after surgery is frequent. Systemic chemotherapy is only the method for treating such patients. No effective agents have been developed for treating gastric cancer to date, except for capecitabine, cisplatin, and trastuzumab combination therapy [3]. However, even with this combination therapy, the median overall survival time was only 13.8 months for human epidermal growth factor receptor 2 (HER2)-positive patients, which is lesser than that for patients with colorectal cancer [3]. Because HER2-positive gastric cancer accounts for only 7–34 % of gastric cancer cases [4], agents with other molecular targets are being eagerly investigated. These include ramucirumab [5] and apatinib [6], which target vascular endothelial growth factor receptor (VEGFR) 2, and sorafenib [7], which acts as a multi-tyrosine kinase inhibitor of VEGFR2 and VEGFR3, platelet-derived growth factor receptor, and RAF kinase. However, these targets are not specifically activated in gastric carcinogenesis.

The unsatisfactory treatment of gastric cancer reflects insufficient understanding of the associated molecular carcinogenesis. In 1994, Helicobacter pylori infection was classified as a definite carcinogen by the International Agency for Research on Cancer [8]. Hence, the mechanisms by which chronic infectious stimuli contribute to this malignancy are under investigation. Recently, it was shown that the CagA protein of H. pylori facilitates nuclear localization of β-catenin in gastric cancers [9]. β-Catenin is a component of Wnt signaling, and its nuclear localization has been observed in 30–58 % of clinical gastric carcinoma specimens [10, 11]. Furthermore, the activation of Wnt signaling by inflammatory stimuli may induce gastric carcinomas in the K19-Wnt1/C2mE transgenic mouse model of gastric cancer (Gan mouse), which expresses transgenic Wnt1, cyclooxygenase (COX) 2, and microsomal prostaglandin E synthase-1 under the control of the K19 promoter [12]. Thus, β-catenin may play a significant role in gastric carcinogenesis.

Hyperactivation of signal transducer and activator of transcription 3 (STAT3) has been observed in many types of cancers [13]. Moreover, in a mouse model of gastric cancer, STAT3 activation promoted carcinogenesis via Toll-like receptor 2 without inflammatory signaling [14]. STAT3 may also participate in gastric carcinogenesis following activation by COX2 in many cancers, such as non-small-cell carcinoma, cholangiocarcinoma, and glioblastoma [15, 16, 17].

In this study, we synthesized novel curcumin analogs and showed that they are potent inhibitors of β-catenin in vitro and in vivo [18, 19]. In our previous studies, phosphorylation of STAT3 was decreased following treatment of pancreatic cancer, breast cancer [20], and multiple myeloma cell lines [21] with the novel curcumin analogs (1E,4E)-1,5-bis-(3,5-bismethoxymethoxyphenyl)penta-1,4-dien-3-one (GO-Y030) and (1E,4E)-1-(4-hydroxy-3,5-dimethoxyphenyl)-5-(3,4,5-trimethoxyphenyl)-penta-1,4-dien-3-one (GO-Y078). Moreover, GO-Y030 suppressed the growth of colorectal cancer stem cells by inhibiting phosphorylated STAT3 (pSTAT3) [22], suggesting that curcumin analogs have anti-inflammatory activities such as those demonstrated with curcumin [23, 24].

Among 86 newly synthesized curcumin analogs, GO-Y030, (1E,4E)-1,5-bis(3,5-dimethoxy-4-methoxymethoxyphenyl)pentadien-3-one (GO-Y031), and GO-Y078 had the most potent antitumor activities [25]. Moreover, in the Apc580D/+ mouse model of colorectal tumorigenesis, GO-Y030 and GO-Y031 suppressed adenoma formation by inhibiting β-catenin [19]. However, no studies have shown whether curcumin analogs have antitumor activity under the low-pH conditions in the stomach. Thus, we investigated the effects of orally administered GO-Y031 in the Gan mouse model of gastric cancer, and we demonstrated effective blockade of β-catenin and promising anticancer efficacy. The present data show that the inhibition of β-catenin and/or STAT3 suppresses gastric carcinogenesis, suggesting that these molecules are efficacious targets for the medicinal treatment of gastric cancer.

Materials and methods


The synthesis of GO-Y031 has been described previously (Fig. 1a) [18]. The high-fat diet (HFD) HFD32 was purchased from CLEA Japan (Tokyo, Japan).
Fig. 1

Experimental overview. a Chemical structure of GO-Y031. MeO indicates a methoxy group and MOMO indicates a methoxymethoxy group. b The experimental schedule. Computed tomography (CT) gastrograms were conducted at 10, 12, 15, 18, and 20 weeks of age. c CT images of the stomachs of Gan mice; dg Histopathology micrographs corresponding to CT images: d, c left; e, c middle; f and g, c right. Bars represent 500 µm in df and 100 µm in g. An asterisk indicates a gastric tumor. HFD high-fat diet, w weeks, ws weeks

Mouse model

K19-Wnt1/C2mE Gan mice were obtained by crossing K19-Wnt1 and K19-C2 mE mice. Genotyping was confirmed as described previously [11]. Daily, Gan mice were fed 5 g of HFD alone or HFD plus 0.5 % (w/w) GO-Y031 from 10 weeks of age (Fig. 1b) and were killed and examined at 20 weeks of age. All animal experiments were performed humanely and complied with the guidelines set by Tohoku University and were approved by the associated ethics committee.

X-ray computed tomography gastrograms

X-ray computed tomography (CT) images of gastric tumors in live mice were examined using a Latheta LCT-200 instrument (Hitachi Aloka, Tokyo, Japan) at 10–12 (pretreatment), 13–15, 16–18, and 20 weeks of age. The radiopaque contrast agent Iopamiron 300 (Bayer Pharma, Osaka, Japan) was administered to mice under anesthesia via gavage and intraperitoneal injection (0.2 ml each, diluted 1:5) immediately before CT scanning.


After the mice had been killed, mouse stomachs were resected and fixed in 10 % neutral buffered formalin, and were then dipped into series of ethanol solutions (70–100 %) and embedded in paraffin. Immunohistochemistry (IHC) was conducted as described previously [19] using the following antibodies: anti-mouse β-catenin (1:1500, C2206, rabbit antiserum, Sigma-Aldrich, Tokyo, Japan), anti-mouse Ki-67 (2 μg/ml, ab15580, rabbit polyclonal antibody, Abcam, Tokyo, Japan), anti-mouse STAT3 (1:500, CST Stat3; 124H6, mouse monoclonal antibody; Cell Signaling Technology Japan, Tokyo, Japan), anti-mouse pSTAT3 (1:100, Tyr705; D3A7, XP rabbit monoclonal antibody, Cell Signaling Technology Japan), anti-mouse p53 protein (1:2,000, CM5, rabbit polyclonal antibody, Vector Laboratories, Burlingame, CA, USA), anti-mouse c-Myc (1:200, 9E10; sc-40, mouse monoclonal antibody, Santa Cruz Biotechnology, Dallas, TX, USA), and anti-mouse δ1-catenin [1:200, EPR357(2), ab92514, rabbit monoclonal antibody, Abcam]. IHC for β-catenin and Ki-67 was conducted by Genostaff (Tokyo, Japan). IHC for CD44 and F4/80 (MCA497R clone A3-1, Serotec, Oxford, UK) was conducted as described previously [11, 26].

Microarray analysis

In the present mouse model, tumors have a protruding appearance and are easily distinguished from the surrounding nontumorous and normal membranes. Thus, normal mucosa was collected during stereomicroscopic examinations.

Total RNA was extracted from background epithelia of three independent mouse stomachs. Equal amounts of RNA from each treatment group were mixed and analyzed. Expression analysis was conducted using the CodeLink™ mouse whole genome bioarray (Applied Microarrays, Tempe, AZ, USA), and data analysis was outsourced to Filgen® (Nagoya, Japan). Data were analyzed using Microarray Data Analysis Tool version 3.2 (Filgen®).

Statistical analysis

Data are shown as the mean ± standard deviation. Differences between groups were identified using Fisher’s exact probability test and Student’s t-test with StatMate III version 3.14 (ATMS, Tokyo, Japan).


Antitumor activity of the curcumin analog GO-Y031 in a mouse model of gastric cancer

Because GO-Y031 is hydrophobic, HFD32 was used to prepare homogeneous mixtures of pellets as described previously [19]. Tumor incidence in HFD-fed Gan mice was examined using CT gastrograms (Fig. 1c), and tumor formations were identified in live mice. All tumors were adenocarcinomas (Fig. 1d–g), and tumor formation was examined chronologically (Fig. 2a). No tumors were observed in mice aged 10–12 weeks (n = 12). However, at 13–15, 16–18, and 20 weeks of age, 25.0, 83.3, and 91.7 % of HFD-fed Gan mice, respectively, harbored gastric tumors. Tumor incidence in HFD-fed Gan mice was suppressed by supplementation with 0.5 % GO-Y031 (Fig. 2a), and at 16–18 and 20 weeks of age, only 30.0 % (n = 10, p = 0.017) and 50.0 % (p = 0.043) of mice, respectively, had gastric tumors. The average tumor height in HFD-fed Gan mice was 3.1 ± 1.5 mm, whereas that in HFD-fed Gan mice also given 0.5 % GO-Y031 was only 1.6 ± 1.5 mm (Fig. 2b, p = 0.03). These data indicate that GO-Y031 may significantly suppress both tumor incidence and growth in Gan mice. In subsequent experiments, we examined anti-inflammatory effects of GO-Y031 in terms of epithelial thickness. However, no differences were found between the two treatment groups, indicating that GO-Y031 exerts potent antitumor activity without acting as an anti-inflammatory agent (data not shown).
Fig. 2

GO-Y031-mediated tumor suppression. a Chronological incidence of gastric tumors in HFD-fed Gan mice also given GO-Y031. Tumor incidence is shown as bars. Asterisks indicate significant differences. b Actual heights of stomach tumors in Gan mice at 20 weeks of age. w weeks

Molecular targets of curcumin analogs

Curcumin and its analogs have multiple potential targets [27]. Thus, we examined molecular targets of GO-Y031 using expression microarrays. Messenger RNA from background epithelia of 20-week-old HFD-fed Gan mice was analyzed in the presence and absence (control) of orally administered 0.5 % GO-Y031. Transcripts with signals below the noise level were excluded, and expression of the remaining transcripts was compared between treatment and control mice. Among 36,000 transcripts, 154 were upregulated to more than 200 % of the level of the control, whereas 351 were downregulated to less than 50 % of the level of the control in HFD-fed Gan mice also given 0.5 % GO-Y031. Transcripts that have been previously analyzed in Gan, K19-Wnt1, and K19-C2mE mice and those related to inflammation are shown in Fig. 3 [12, 28]. In addition, transcripts that were significantly regulated by treatment with GO-Y031 and were related to Wnt signaling or malignancy are indicated in Fig. 3. Treatment with GO-Y031 did not affect the expression of transcripts related to inflammation, including COX1, prostaglandin E synthase 2, keratin 8, chemokine (C–C motif) ligand 4, forkhead box protein A1, GATA-binding protein 3, and ephrin type B receptor 3 (Fig. 3). However, GO-Y031 treatment decreased the transcription of β-catenin, c-Myc, STAT3, and δ1-catenin to 58, 50, 17, and 40 % of the level of the control, respectively (Fig. 3). The expression of p53 was decreased to 36 % of the level of the control (Fig. 3).
Fig. 3

Comparison of expression profiles between normal mucosa of GO-Y031-treated Gan mice and control mice. Data are expressed relative to the control. Red bars indicate suppression to below 50 % of the level of the control. Transcripts related to prostaglandin and cytokine signaling are shown below PGs and transcripts related to Wnt signaling are shown below Wnt. Apc adenomatous polyposis coli, Ccl 4 chemokine (C–C motif) ligand 4, CCnd2 cyclin D2, Cox 1 cyclooxygenase 1, Ctnnb1 β-catenin, Ctnnd1 δ1-catenin, Ephb3 ephrin type B receptor 3, Foxa1 forkhead box protein A1, Gata3 GATA-binding protein 3, Krt 5 keratin 5, Krt 8 keratin 8, mRNA messenger RNA, Ptges2 prostaglandin E synthase 2, Stat 3 signal transducer and activator of transcription 3, Trp 53 p53

Suppression of β-catenin by the curcumin analog GO-Y031

IHC indicated that cytosolic β-catenin-positive cells in the corpus gastric unit were less abundant in the background epithelia of Gan mice fed HFD plus 0.5 % GO-Y031 than in those of Gan mice fed HFD alone (9.90 ± 4.58 % vs 37.8 ± 8.77 %, p = 0.00023; Figs. 4a, b, 5a). Importantly, nuclear staining of β-catenin was observed in gastric cancer tissues (Fig. S1a). Because accumulated cytosolic β-catenin is transferred to the nucleus and acts as an oncogenic transactivator that promotes hyperproliferation, we examined Ki-67 expression as a marker of growth. Although 12.7 ± 9.38 % of cells in the corpus gastric unit in 0.5 % GO-Y031-treated HFD-fed Gan mice were Ki-67 positive, 42.0 ± 8.81 % of these cells in control mice were Ki-67 positive (p = 0.00094, Figs. 4c, d, 5b). Similarly, Ki-67 signals were abundantly observed in gastric cancer tissues (Fig. S1b). These data indicate that orally administered GO-Y031 acts as a β-catenin inhibitor in the stomach and may suppress the incidence and growth of malignant cells. Importantly, β-catenin levels were not reduced in nontransgenic wild-type mice (Fig. S2a).
Fig. 4

Immunohistochemical analyses of Wnt signaling. a Expression of β-catenin in normal mucosa from HFD-fed Gan mice. The inset shows a higher magnification of the red rectangular area, and triangles indicate cells that were positive for nuclear and cytosolic β-catenin. b β-Catenin in normal mucosa from GO-Y031-treated Gan mice. The inset shows a higher magnification, and triangles indicate cells with decreased cytosolic β-catenin staining. c Ki-67 expression in normal mucosa from HFD-fed Gan mice. The red rectangle shows the Ki-67-positive intracellular area. d Ki-67 expression in normal mucosa from GO-Y031-treated Gan mice. The red rectangle shows decreased Ki-67-positive areas. The bars represent 100 μm

Fig. 5

Quantitative analyses of immunoreactivity is presented as a percentage of positive cell areas. a Expression of β-catenin. b Expression of Ki-67. c Expression of STAT3. d Expression of phophorylated STAT3 (pSTAT3). The bars represent standard deviations

Suppression of STAT3 activation by the curcumin analog GO-Y031

Expression analyses of STAT3 were confirmed by IHC. In these experiments, 25.9 ± 8.14 % of the cells in the corpus gastric unit were STAT3 positive in 0.5 % GO-Y031-treated HFD-fed Gan mice, whereas 57.8 ± 19.9 % of the cells were STAT3 positive in control mice (p = 0.025, Figs. 5c, 6a). Moreover, STAT3 signals were more pronounced in the cytosol and nucleus of cells from control mice than in the cytosol and nucleus of cells from 0.5 % GO-Y031-treated HFD-fed Gan mice. Nuclear transfer of STAT3 is dependent on the phosphorylation of STAT3 at tyrosine 705, which results in the activation of STAT3 [29]. Hence, IHC was conducted using a specific antibody for this pSTAT3. In these experiments, 0.97 ± 1.67 % of the cells in the corpus gastric units of 0.5 % GO-Y031-treated HFD-fed Gan mice were pSTAT3 positive, whereas 28.2 ± 8.36 % of the cells in control mice were pSTAT3 positive (p = 0.0052, Figs. 5d, 6c, d). STAT3 and pSTAT3 signals were abundantly observed in gastric cancer tissues (Fig. S1c, d). Hence, in agreement with the present microarray data, treatment with GO-Y031 significantly decreased the numbers of pSTAT3-activated cells in mice with gastric cancer, indicating that this curcumin analog may inhibit the phosphorylation of STAT3. Importantly, pSTAT3 signals were not detected in nontransgenic wild-type mice (Fig. S2c).
Fig. 6

Immunohistochemical analyses of STAT3. a Expression of STAT3 in normal mucosa of HFD-fed Gan mice. b STAT3 in normal mucosa from GO-Y031-treated Gan mice. c Expression of pSTAT3 (Tyr705) in normal mucosa from HFD-fed Gan mice. The inset shows a higher magnification of the red rectangular area. Red arrows indicate typical nuclear pSTAT3 signals. d Expression of pSTAT3 (Tyr705) in normal mucosa from GO-Y031-treated Gan mice. The inset shows a higher magnification of the red rectangular area. No signals were detected in epithelial cells. The bars represent 100 μm

CD44 is a major cell adhesion molecule that participates in various physiological events, including lymphocyte homing, wound healing, and cell migration as well as in cancer cell growth and metastasis [30]. Accordingly, CD44 has been implicated in cancer stem cell maintenance during gastric carcinogenesis [26]. Recently, it was shown that CD44 is upregulated by β-catenin [9]. Thus, we examined the expression of CD44 in the background mucosa of Gan mice. Although CD44 messenger RNA was not detectable in the present microarray experiments, compared with control mice, areas with CD44-positive IHC signals were reduced in 0.5 % GO-Y031-treated HFD-fed Gan mice (Fig. 7a, b), indicating that GO-Y031 reduces CD44 expression in the background epithelia of Gan mice.
Fig. 7

Immunohistochemical analyses of CD44 and F4/80. a Expression of CD44 in normal mucosa from HFD-fed Gan mice. b CD44 expression in normal mucosa from GO-Y031-treated Gan mice. c F4/80 expression in normal mucosa from HFD-fed Gan mice. d F4/80 expression in normal mucosa from GO-Y031-treated Gan mice. e Numbers of F4/80-positive macrophages in five randomly selected areas from each treatment group. The bars represent standard deviations

Other candidate protein targets

IHC for p53 (Fig. S3), δ1-catenin, and c-Myc did not show any differences between treatment and control groups (data not shown), although p53 was undetectable in gastric cancer tissues from Gan mice (Fig. S1e). These observations were inconsistent with the present microarray data, which did not confirm the downregulation of these genes by GO-Y031. In further IHC experiments with an F4/80 antibody [11], macrophage infiltration was abundant in gastric mucosa of Gan mice, reflecting increased prostaglandin E2 expression [11]. Compared with control HFD-fed Gan mice, treatment of Gan mice with GO-Y031 significantly suppressed macrophage infiltration (Fig. 7c–e), indicating that GO-Y031 has anti-inflammatory effects that may be similar to those of curcumin.

Safety issues

The safety of GO-Y031 was confirmed in the present study, with no agent-related adverse events, as shown previously [19].


Transgenic expression of β-catenin in gastric epithelia may induce gastric cancer, and in this study, we clearly showed that suppression of β-catenin inhibits gastric carcinogenesis. Oshima established the present mouse model, and cancers in these Gan mice were recently shown to belong to the intestinal type according to Laurén’s classification [31]. In this study, we confirmed that β-catenin is a candidate target for the treatment of gastric cancer and showed the therapeutic potential of the curcumin analog GO-Y031. Initially, suppression of STAT3 and β-catenin expression was observed in the Gan mouse model of gastric cancer, and subsequent immunohistochemical analyses indicated suppression of STAT3 phosphorylation. Previous reports showed that β-catenin influences STAT3 and vice versa [32, 33, 34, 35]. In our previous studies, the curcumin analog GO-Y030 inhibited β-catenin in the mouse colonic epithelium, inhibited STAT3 phosphorylation in colon cancer stem cells, and inhibited the growth of colon cancer stem cell xenografts in nude mice. Hence, similarly to curcumin, the curcumin analog GO-Y030 has multiple protein targets [36]. In the present study, GO-Y031 targeted both β-catenin and STAT3, which are transcriptional regulators that control various downstream molecules, such as c-Myc, cyclin D1, vascular endothelial growth factor, and survivine, and contribute to cancer cell growth and survival [37, 38]. Furthermore, cross-linking between β-catenin and STAT3 may compensate for single inhibition of one or the other, leading to drug resistance. Thus, simultaneous inhibition of these two major molecules with GO-Y031 may result in improved inhibition of gastric carcinogenesis. Curcumin analogs may also inhibit gastric tumors under conditions of low pH. However, it remains unknown whether curcumin analogs can improve survival in mice with gastric cancer, and GO-Y031 was not curative in Gan mice. Potentially, this may reflect the carcinogenic drive of the transgenes Ptgs2 (encoding COX2), Ptges (encoding microsomal prostaglandin E synthase 1), and Wnt1 in whole gastric epithelia of Gan mice, which leads to 100 % tumor incidence and more aggressive cancers than the sporadic gastric cancers observed in humans [12]. Nonetheless, the present data warrant assessment of the survival benefits of curcumin analogs in humans, particularly because no inhibitors of β-catenin or STAT3 have been approved for clinical use as chemotherapeutic agents for cancer. Recently, an inhibitor of the CREB-binding protein–β-catenin interaction (ICG-001) was examined in a phase 1/phase 2 study as a potent inhibitor of β-catenin for the treatment of acute lymphoblastic leukemia, chronic myeloid leukemia, pancreatic cancer, and other solid tumors [39, 40]. Numerous studies have shown that STAT3 inhibitors lead to human tumor regression in animal models [22, 41]. However, although preclinical and phase 0 studies of STAT3 inhibitors have progressed with urgency, no such agents have been approved [42]. The present data indicate that the curcumin analog GO-Y031 may be a promising lead agent for the treatment of gastric cancer, acting as a β-catenin and/or STAT3 inhibitor. Although the effects of CD44 inhibition in cancer therapy remain controversial, numerous reports have shown effective reduction of malignancies, including colon, mammary, and ovarian cancers, following treatment with CD44 inhibitors [40]. The downregulation of CD44 after treatment with GO-Y031 suggests that curcumin analogs inhibit gastric cancer stem cells and reflect the inhibition of STAT3 and/or CD44 in colorectal cancer stem cells [22]. In agreement, knockdown of Stat3 resulted in the downregulation of the stem cell markers Oct-4, Sox-2, and CD44 [43].

Infection with H. pylori is a common cause of gastric cancer, and curcumin has been reported to exhibit antimicrobial activity against H. pylori [44]. Recently, the antimicrobial activity of curcumin against H. pylori was shown to differ between strains, with minimum inhibitory concentrations of 5–50 μg/ml [45]. Moreover, curcumin has been shown to ameliorate H. pylori infection in rodents [46]. However, the antimicrobial activity of GO-Y031 against H. pylori requires further study.

The safety of diarylpentanoid-type curcumin analogs has been shown in a recent study, and the diarylpentanoid curcumin analog 1,5-bis(4-hydroxy-3-methoxyphenyl)-1,4-pentadiene-3-one (GO-Y022) has been detected in cooked curry [47]. Thus, some deketone curcumin analogs such as diarylpentanoids may be safe to eat.



This study was partially supported by the Japan Society for the Promotion of Science [Grant-in-Aid for Scientific Research (C) 22501041 to Y.U., Y.I., and H.S.], the Joint Research Project of the Cancer Research Institute of Kanazawa University (M.O. and H.S.), and Nippon Carbide Industries (Tokyo, Japan). The authors also thank Enago ( for review and revision of the language.

Supplementary material

10120_2014_434_MOESM1_ESM.tif (1.5 mb)
Fig. S1 Immunohistochemical analysis of β-catenin (a), Ki-67 (b), STAT3 (c), pSTAT3 (d), and p53 (e) of gastric cancer in Gan mice. The bars represent 50 μm (a, b, e), and 100 μm (c, d)
10120_2014_434_MOESM2_ESM.tif (1.5 mb)
Fig. S2 Immunohistochemical analysis of β-catenin (a), STAT3 (b), and pSTAT3 (c) in nontransgenic mice (TIFF 1520 kb)
10120_2014_434_MOESM3_ESM.tif (1.5 mb)
Fig. S3 Expression of p53 in background normal mucosa from Gan mice fed HFD (a) or GO-Y031 (b). The bar represents 100 μm (TIFF 1520 kb) (TIFF 1520 kb)


  1. 1.
    Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer. 2010;127:2893–917.CrossRefPubMedGoogle Scholar
  2. 2.
    Jemal A, Bray F, Center MM, Ferlay G, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61:69–90.CrossRefPubMedGoogle Scholar
  3. 3.
    Bang YJ, Van Cutsem E, Feyereislova A, Chung HC, Shen L, Sawaki A, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet. 2010;376:687–97.CrossRefPubMedGoogle Scholar
  4. 4.
    Yamamoto H, Wamaatanabe Y, Maehata T, Morita R, Yoshida Y, Oikawa R, et al. An updated review of gastric cancer in the next-generation sequencing era: insights from bench to bedside and vice versa. World J Gastroenterol. 2014;20:3927–37.PubMedCentralCrossRefPubMedGoogle Scholar
  5. 5.
    Fuchs CS, Tomasek J, Yong CJ, Dumitru F, Passalacqua R, Goswami C, et al. Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial. Lancet. 2014;383:31–9.CrossRefPubMedGoogle Scholar
  6. 6.
    Li J, Qin S, Xu J, Guo W, Xiong J, Bai Y, et al. Apatinib for chemotherapy-refractory advanced metastatic gastric cancer: results from a randomized, placebo-controlled, parallel-arm, phase II trial. J Clin Oncol. 2013;31:3219–25.CrossRefPubMedGoogle Scholar
  7. 7.
    Sun W, Powell M, O’Dwyer PJ, Catalano P, Ansari RH, Benson AB 3rd. Phase II study of sorafenib in combination with docetaxel and cisplatin in the treatment of metastatic or advanced gastric and gastroesophageal junction adenocarcinoma: ECOG 5203. J Clin Oncol. 2010;28:2947–51.PubMedCentralCrossRefPubMedGoogle Scholar
  8. 8.
    IARC Working Group on the Evaluation of Carcinogenic Risks to Humans. Schistosomes, liver flukes and Helicobacter pylori. Vol. 61, IARC monographs on the evaluation of carcinogenic risks to humans. Lyon: IARC; 1994. p. 77–240.Google Scholar
  9. 9.
    Udhayakumar G, Jayanthi V, Devaraj N, Devaraj H. Nuclear translocation of β-catenin correlates with CD44 upregulation in Helicobacter pylori-infected gastric carcinoma. Mol Cell Biochem. 2011;357:283–93.CrossRefPubMedGoogle Scholar
  10. 10.
    Clements WM, Wang J, Sarnaik A, Kim OJ, MacDonald J, Fenoglio-Preiser C, et al. β-Catenin mutation is a frequent cause of Wnt pathway activation in gastric cancer. Cancer Res. 2002;62:3503–6.PubMedGoogle Scholar
  11. 11.
    Oshima H, Matsunaga A, Fujimura T, Tsukamoto T, Taketo MM, Oshima M. Carcinogenesis in mouse stomach by simultaneous activation of the Wnt signaling and prostaglandin E2 pathway. Gastroenterology. 2006;131:1086–95.CrossRefPubMedGoogle Scholar
  12. 12.
    Oshima H, Itadani H, Kotani H, Taketo MM, Oshima M. Induction of prostaglandin E2 pathway promotes gastric hamartoma development with suppression of bone morphogenetic protein signaling. Cancer Res. 2009;69:2729–33.CrossRefPubMedGoogle Scholar
  13. 13.
    Sansone P, Bromberg J. Targeting the interleukin-6/Jak/Stat pathway in human malignancies. J Clin Oncol. 2012;30:1005–14.PubMedCentralCrossRefPubMedGoogle Scholar
  14. 14.
    Tye H, Kennedy CL, Najdovska M, McLeod L, McCormack W, Hughes N, et al. STAT3-driven upregulation of TLR2 promotes gastric tumorigenesis independent of tumor inflammation. Cancer Cell. 2012;22:466–78.CrossRefPubMedGoogle Scholar
  15. 15.
    Dalwadi H, Krysan K, Heuze-Vourc’h N, Dohadwala M, Elashoff D, Sharma S, et al. Cyclooxygenase-2-dependent activation of signal transducer and activator of transcription 3 by interleukin-6 in non-small cell lung cancer. Clin Cancer Res. 2005;11:7674–82.CrossRefPubMedGoogle Scholar
  16. 16.
    Han C, Demetris AJ, Stolz DB, Xu L, Lim K, Wu T. Modulation of Stat3 activation by the cytosolic phospholipase A2α and cyclooxygenase-2-controlled prostaglandin E2 signaling pathway. J Biol Chem. 2006;281:24831–46.CrossRefPubMedGoogle Scholar
  17. 17.
    Lo HW, Cao X, Zhu H, Ali-Osman F. Cyclooxygenase-2 is a novel transcriptional target of the nuclear EGFR-STAT3 and EGFRvIII-STAT3 signaling axes. Mol Cancer Res. 2010;8:232–45.PubMedCentralCrossRefPubMedGoogle Scholar
  18. 18.
    Ohori H, Yamakoshi H, Tomizawa M, Shibuya M, Kakudo Y, Takahashi A, et al. Synthesis and biological analysis of new curcumin analogues bearing an enhanced potential for the medicinal treatment of cancer. Mol Cancer Ther. 2006;5(10):2563–71.CrossRefPubMedGoogle Scholar
  19. 19.
    Shibata H, Yamakoshi H, Sato A, Ohori H, Kakudo Y, Kudo C, et al. Newly synthesized curcumin analog has improved potential to prevent colorectal carcinogenesis in vivo. Cancer Sci. 2009;100:956–60.CrossRefPubMedGoogle Scholar
  20. 20.
    Hutzen B, Friedman L, Sobo M, Lin L, Cen L, De Angelis S, et al. Curcumin analogue GO-Y030 inhibits STAT3 activity and cell growth in breast and pancreatic carcinomas. Int J Oncol. 2009;35:867–72.PubMedGoogle Scholar
  21. 21.
    Kudo C, Yamakoshi H, Sato A, Ohori H, Ishioka C, Iwabuchi Y, et al. Novel curcumin analogs, GO-Y030 and GO-Y078, are multi-targeted agents with enhanced abilities for multiple myeloma. Anticancer Res. 2011;31:3719–26.PubMedGoogle Scholar
  22. 22.
    Lin L, Liu Y, Li H, Li PK, Fuchs J, Shibata H, et al. Targeting colon cancer stem cells using a new curcumin analogue, GO-Y030. Br J Cancer. 2011;105:212–20.PubMedCentralCrossRefPubMedGoogle Scholar
  23. 23.
    Hong J, Bose M, Ju J, Ryu JH, Chen X, Sang S, et al. Modulation of arachidonic acid metabolism by curcumin and related β-diketone derivatives: effects on cytosolic phospholipase A2, cyclooxygenases and 5-lipoxygenase. Carcinogenesis. 2004;25:1671–9.CrossRefPubMedGoogle Scholar
  24. 24.
    Jurenka JS. Anti-inflammatory properties of curcumin, a major constituent of Curcuma longa: a review of preclinical and clinical research. Altern Med Rev. 2009;14:141–53.PubMedGoogle Scholar
  25. 25.
    Kudo C, Yamakoshi H, Sato A, Nanjo H, Ohori H, Ishioka C, et al. Synthesis of 86 species of 1,5-diaryl-3-oxo-1,4-pentadienes analogs of curcumin can yield a good lead in vivo. BMC Pharmacol. 2011. doi: 10.1186/1471-2210-11-4.PubMedCentralPubMedGoogle Scholar
  26. 26.
    Ishimoto T, Oshima H, Oshima M, Kai K, Torii R, Masuko T, et al. CD44 + slow-cycling tumor cell expansion is triggered by cooperative actions of Wnt and prostaglandin E2 in gastric tumorigenesis. Cancer Sci. 2010;101:673–8.CrossRefPubMedGoogle Scholar
  27. 27.
    Surh YJ. Cancer chemoprevention with dietary phytochemicals. Nat Rev Cancer. 2003;3:768–80.CrossRefPubMedGoogle Scholar
  28. 28.
    Oshima H, Oshima M, Inaba K, Taketo MM. Hyperplastic gastric tumors induced by activated macrophages in COX-2/mPGES-1 transgenic mice. EMBO J. 2004;23:1669–78.PubMedCentralCrossRefPubMedGoogle Scholar
  29. 29.
    Yuan ZL, Guan YJ, Wang L, Wei W, Kane AB, Chin YE. Central role of the threonine residue within the p+1 loop of receptor tyrosine kinase in STAT3 constitutive phosphorylation in metastatic cancer cells. Mol Cell Biol. 2004;24:9390–400.PubMedCentralCrossRefPubMedGoogle Scholar
  30. 30.
    Naor D, Nedvetzki S, Golan I, Melnik L, Faitelson Y. CD44 in cancer. Crit Rev Clin Lab Sci. 2002;39:527–79.CrossRefPubMedGoogle Scholar
  31. 31.
    Itadani H, Oshima H, Oshima M, Kotani H. Mouse gastric tumor models with prostaglandin E2 pathway activation show similar gene expression profiles to intestinal-type human gastric cancer. BMC Genomics. 2009;10:615–22.PubMedCentralCrossRefPubMedGoogle Scholar
  32. 32.
    Yan S, Zhou C, Zhang W, Zhang G, Zhao X, Yang S, et al. β-Catenin/TCF pathway upregulates STAT3 expression in human esophageal squamous cell carcinoma. Cancer Lett. 2008;271:85–97.CrossRefPubMedGoogle Scholar
  33. 33.
    Anand M, Lai R, Gelebart P. β-catenin is constitutively active and increases STAT3 expression/activation in anaplastic lymphoma kinase-positive anaplastic large cell lymphoma. Haematologica. 2011;96:253–61.PubMedCentralCrossRefPubMedGoogle Scholar
  34. 34.
    Fragoso MA, Patel AK, Nakamura RE, Yi H, Surapaneni K, Hackam AS. The Wnt/β-catenin pathway cross-talks with STAT3 signaling to regulate survival of retinal pigment epithelium cells. PLoS One. 2012. doi: 10.1371/journal.pone.0046892.Google Scholar
  35. 35.
    Armanious H, Gelebart P, Mackey J, Ma Y, Lai R, et al. STAT3 upregulates the protein expression and transcriptional activity of β-catenin in breast cancer. Int J Clin Exp Pathol. 2010;3:654–64.PubMedCentralPubMedGoogle Scholar
  36. 36.
    Shibata H, Iwubuchi Y. Challenges in establishing potent cancer chemotherapy using newly synthesized 1,5-diaryl-3-oxo-1,4-pentadiene analogs of curcumin. In: Sasaki J, Kikuchi M, editors. Curcumin biosynthesis, medical uses and health benefits. New York: Nova; 2012. p. 177–91.Google Scholar
  37. 37.
    Behrens J. Control of β-catenin signaling in tumor development. Ann N Y Acad Sci. 2000;910:21–33.CrossRefPubMedGoogle Scholar
  38. 38.
    Aggarwal BB, Sethi G, Ahn KS, Sandur SK, Pandey MK, Kunnumakkara AB, et al. Targeting signal-transducer-and-activator-of-transcription-3 for prevention and therapy of cancer: modern target but ancient solution. Ann N Y Acad Sci. 2006;1091:151–69.CrossRefPubMedGoogle Scholar
  39. 39.
    Gang EJ, Hsieh YT, Pham J, Zhao Y, Nguyen C, Huantes S, et al. Small-molecule inhibition of CBP/catenin interactions eliminates drug-resistant clones in acute lymphoblastic leukemia. Oncogene. 2013. doi: 10.1038/onc.2013.169.PubMedCentralPubMedGoogle Scholar
  40. 40.
    Nero TL, Morton CJ, Holien JK, Wielens J, Parker MW. Oncogenic protein interfaces: small molecules, big challenges. Nat Rev Cancer. 2014;4:248–62.CrossRefGoogle Scholar
  41. 41.
    McMurray JS, Mandal PK, Liao WS, Klostergaard J, Robertson FM. The consequences of selective inhibition of signal transducer and activator of transcription 3 (STAT3) tyrosine705 phosphorylation by phosphopeptide mimetic prodrugs targeting the Src homology 2 (SH2) domain. JAKSTAT. 2012;1:263–347.PubMedCentralPubMedGoogle Scholar
  42. 42.
    Page BD, Ball DP, Gunning PT. Signal transducer and activator of transcription 3 inhibitors: a patent review. Expert Opin Ther Pat. 2011;21:65–83.CrossRefPubMedGoogle Scholar
  43. 43.
    Chung SS, Giehl N, Wu Y, Vadgama JV. STAT3 activation in HER2-overexpressing breast cancer promotes epithelial-mesenchymal transition and cancer stem cell traits. Int J Oncol. 2014;44:403–11.PubMedCentralPubMedGoogle Scholar
  44. 44.
    Mahady GB, Pendland SL, Yun G, Lu ZZ. Turmeric (Curcuma longa) and curcumin inhibit the growth of Helicobacter pylori, a group 1 carcinogen. Anticancer Res. 2002;22:4179–81.PubMedGoogle Scholar
  45. 45.
    De R, Kundu P, Swarnakar S, Ramamurthy T, Chowdhury A, Nair GB, et al. Antimicrobial activity of curcumin against Helicobacter pylori isolates from India and during infections in mice. Antimicrob Agents Chemother. 2009;53:1592–7.PubMedCentralCrossRefPubMedGoogle Scholar
  46. 46.
    Sintara K, Thong-Ngam D, Patumraj S, Klaikeaw N, Chatsuwan T. Curcumin suppresses gastric NF-kappaB activation and macromolecular leakage in Helicobacter pylori-infected rats. World J Gastroenterol. 2010;16:4039–46.PubMedCentralCrossRefPubMedGoogle Scholar
  47. 47.
    Dahmke IN, Boettcher SP, Groh M, Mahlknecht U. Cooking enhances curcumin anti-cancerogenic activity through pyrolytic formation of “deketene curcumin”. Food Chem. 2014;151:514–9.CrossRefPubMedGoogle Scholar

Copyright information

© The Author(s) 2014

Open AccessThis article is distributed under the terms of the Creative Commons Attribution License which permits any use, distribution, and reproduction in any medium, provided the original author(s) and the source are credited.

Authors and Affiliations

  • Yoshihiko Uehara
    • 1
  • Masahiro Inoue
    • 2
  • Koji Fukuda
    • 2
  • Hiroyuki Yamakoshi
    • 3
  • Yoshio Hosoi
    • 1
  • Hiroaki Kanda
    • 4
  • Masanobu Oshima
    • 5
  • Yoshiharu Iwabuchi
    • 3
  • Hiroyuki Shibata
    • 2
    Email author
  1. 1.Department of Cell Biology, Graduate School of MedicineTohoku UniversitySendaiJapan
  2. 2.Department of Clinical Oncology, Graduate School of MedicineAkita UniversityAkitaJapan
  3. 3.Department of Organic Chemistry, Graduate School of Pharmaceutical ScienceTohoku UniversitySendaiJapan
  4. 4.Division of Pathology, Cancer InstituteJapanese Foundation for Cancer ResearchTokyoJapan
  5. 5.Division of Genetics, Cancer Research InstituteKanazawa UniversityKanazawaJapan

Personalised recommendations